Data Visualizations Working Group Wrap-Up March 21st, 2017.

Slides:



Advertisements
Similar presentations
6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Advertisements

UK Renal Registry 16th Annual Report Figure 5.1. Flow chart showing number of patients included in the various analyses.
Qi Jiang and Liping Huang on Behalf of the Adverse Event Sub Team
Decision to do an RCA VA National Center for Patient Safety REV The RCA Process An Overview The RCA Process An Overview.
Usability Test by Knowing User’s Every Move - Bharat chaitanya.
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
Treatment Plan.
Jasper Ogwal-Okeng Gulu University Research Workshop 3 rd -6 th March 08.
1 TYSABRI Risk Management Plan Will Maier, PhD Senior Director, Epidemiology.
Second Annual Japan CDISC Group (JCG) Meeting 28 January 2004 Julie Evans Director, Technical Services.
Interoperability Showcase In collaboration with IHE Use Case 3 Care Theme: Leveraging National Healthcare Registries in Care Delivery Biosurveillance Monitoring.
ABC Elementary Food Safety and Sanitation Valerie Kohl Sanitation Accountability Director.
National Competent Authorities in Member States
ACCREDITED CONSULTANTS PVT LTD. (ACPL) WELCOMES YOU Your PHARMACOVIGILANCE PARTNER.
Base Line Health Facility Audit Presentation to the Select Committee on Social Service Date 19 March 2013.
PREPARED BY: SUNIL PAUDEL NHU NGUYEN MUATH ABDULRAHMAN IMPLEMENTATION OF CLINICAL DATA WAREHOUSE SYSTEM.
Annual Report Dorothy J. Minear, Ph.D. January 20,
Automated Grid Monitoring for LHCb Experiment through HammerCloud Bradley Dice Valentina Mancinelli.
1 st QUARTERLY PERFORMANCE REPORT ON CUSTOMISED SECTOR.
Adding SubtractingMultiplyingDividingMiscellaneous.
Cardiovascular Health Research Unit, Seattle, WA IOM recommendations on drug safety: relevance for vaccines? Bruce M Psaty, MD, PhD.
Primary Goal: To support case detection and investigation for the reportable infectious diseases (conditions) using electronic information exchanges between.
An initiative of the International Rare Diseases Research Consortium-IRDiRC Spanish Rare Diseases Registries Research Network - SpainRDR
INTERGROUP STUDY 0148 BMS CA Effect of TAXOL® (paclitaxel) and Doxorubicin Dose on Disease Free and Overall Survival of Patients with Node Positive.
National Cancer Intelligence Network What data are available, and how are they accessed? Cancer Roadshow (London) 13 th April 2015 Vivian Mak, Information.
The Global Partnership Monitoring Framework Process: What, when, by whom? Global Partnership monitoring workshop Copenhagen, June 2013.
Adverse Event (AE) Coding Data mining and cleaning Medical literature screening and report writing Cleaning juggled Drug- AE data and converting to machine.
How to include additional information in ODV and CDI formats
By: Samuel Oswald Hunter Supervisor: Mr Barry Irwin
Midwest Biopharmaceutical Statistics Workshop
Current and Future State of the IMPROVE Website
Within Trial Decisions: Unblinding and Termination
Helen Lee, European Commission
مبررات إدخال الحاسوب في رياض الأطفال
UK Renal Registry 13th Annual Report
Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams
7. aDSM slides - Indicators of aDSM implementation and programme management Multi-partner training package on active TB drug safety monitoring and management.
Figure 1 Metabolic profiling as a tool for studying rheumatic diseases
Progress report on the SAI Capacity Development Database
UK Renal Registry 11th Annual Report
Web-based Biosurveillance Decision Support Tools: AIDO and RED Alert
Oral Anticoagulation in AF
Indiana Traumatic Brain Injury (TBI) Advisory Board
UK Renal Registry 11th Annual Report 2008
Advancing the Treatment of IBD With Biologics
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Data Visualizations Working Group
BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.
Christine Halleux, MD, PhD
21twelveinteractive.com/ twitter.com/21twelveI/ facebook.com/21twelveinteractive/ linkedin.com/company/21twelve-interactive/ pinterest.com/21twelveinteractive/
UK Renal Registry 11th Annual Report
Fig. 1. scRNA-seq applications in cancer medicine.
Risk-Based Monitoring (RBM) and Data Quality Analysis (CSM) of Clinical Trials using
Update on the Management of Atopic Dermatitis
Aspects of pharmacovigilance: Development Safety Update Report (DSUR)
Adding with 9’s.
Adding with 10’s.
Standard Analyses and Displays for Common Clinical Trial Data:
ANZDATA Registry 41st Annual Report Highlights of End Stage Kidney Disease in Australia and New Zealand Data to 31-Dec-2017.
UK Renal Registry 14th Annual Report
UK Renal Registry 12th Annual Report
Adding ____ + 10.
Transmission Workstream 4th December 2008
Research and teaching, areas
Consultant Clinical Biochemist
UK Renal Registry 12th Annual Report
UK Renal Registry 13th Annual Report
Table 1. Benefits of data visualization tools
UK Renal Registry 11th Annual Report
Presentation transcript:

Data Visualizations Working Group Wrap-Up March 21st, 2017

Use Cases for Data Visualizations Group 1 Best Practices for Interactive Analyses for Decision-making & Submissions Ongoing Aggregated Safety Signal Detection Registries & Rare Diseases help w ad hoc requests Traceability Efficacy/QC visualizations Group 2 Use of Data Visualizations for Subject Level Data Review Patient Narratives Patient Progress Patient Profiles Efficacy Viz for Analyses Viz for QC & Analysis & Reporting Traceability of TLF/G RWD/RWE Group 3 Use of Data Visualizations for Data Anomaly Detection Data Quality Anomaly Detection Data Cleaning Metrics & Operational Performance Central Monitoring Group 4 Use of Data Visualizations for Study Level Data Review Methods and Tools for Study Narratives Annual Safety Report Drug Safety Update Report